Seeyond Purchases 98 Shares of DaVita Inc. (NYSE:DVA)

Seeyond increased its position in DaVita Inc. (NYSE:DVA) by 0.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,876 shares of the company’s stock after acquiring an additional 98 shares during the quarter. Seeyond’s holdings in DaVita were worth $2,634,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. LSV Asset Management increased its holdings in shares of DaVita by 0.3% during the 2nd quarter. LSV Asset Management now owns 2,335,635 shares of the company’s stock worth $281,280,000 after purchasing an additional 7,300 shares during the period. Factorial Partners LLC increased its holdings in shares of DaVita by 10,677.0% during the 1st quarter. Factorial Partners LLC now owns 1,584,219 shares of the company’s stock worth $14,700,000 after purchasing an additional 1,569,519 shares during the period. Gates Capital Management Inc. increased its holdings in shares of DaVita by 26.3% during the 1st quarter. Gates Capital Management Inc. now owns 1,402,841 shares of the company’s stock worth $151,184,000 after purchasing an additional 292,443 shares during the period. Bank of Montreal Can increased its holdings in shares of DaVita by 17.6% during the 2nd quarter. Bank of Montreal Can now owns 776,956 shares of the company’s stock worth $94,883,000 after purchasing an additional 116,008 shares during the period. Finally, Morgan Stanley increased its holdings in shares of DaVita by 36.0% during the 1st quarter. Morgan Stanley now owns 641,977 shares of the company’s stock worth $69,186,000 after purchasing an additional 170,014 shares during the period. Hedge funds and other institutional investors own 86.52% of the company’s stock.

In related news, CFO Joel Ackerman sold 37,760 shares of the business’s stock in a transaction that occurred on Thursday, August 5th. The shares were sold at an average price of $131.36, for a total transaction of $4,960,153.60. Following the completion of the sale, the chief financial officer now directly owns 35,500 shares of the company’s stock, valued at $4,663,280. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Paula A. Price sold 790 shares of the business’s stock in a transaction that occurred on Thursday, August 5th. The stock was sold at an average price of $132.66, for a total transaction of $104,801.40. Following the sale, the director now directly owns 380 shares of the company’s stock, valued at $50,410.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,915 shares of company stock valued at $5,113,533. Insiders own 0.69% of the company’s stock.

NYSE:DVA traded up $1.01 on Thursday, reaching $110.97. The stock had a trading volume of 8,555 shares, compared to its average volume of 682,472. The company has a market capitalization of $11.63 billion, a P/E ratio of 14.64, a price-to-earnings-growth ratio of 1.00 and a beta of 1.28. DaVita Inc. has a 1-year low of $84.14 and a 1-year high of $136.48. The company has a quick ratio of 1.62, a current ratio of 1.67 and a debt-to-equity ratio of 6.01. The stock has a fifty day moving average price of $125.17 and a 200-day moving average price of $120.99.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 3rd. The company reported $2.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.14 by $0.50. DaVita had a net margin of 7.47% and a return on equity of 61.00%. The company had revenue of $2.92 billion during the quarter, compared to the consensus estimate of $2.88 billion. Sell-side analysts predict that DaVita Inc. will post 9.22 earnings per share for the current fiscal year.

Several analysts have recently weighed in on DVA shares. Cowen started coverage on shares of DaVita in a research report on Thursday, September 9th. They set a “market perform” rating and a $145.00 target price on the stock. William Blair reiterated a “market perform” rating on shares of DaVita in a research report on Wednesday, August 4th. Barclays reiterated an “equal weight” rating and set a $146.00 target price (up from $135.00) on shares of DaVita in a research report on Thursday, August 12th. Truist decreased their target price on shares of DaVita from $145.00 to $125.00 and set a “hold” rating on the stock in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of DaVita from $150.00 to $207.00 and gave the company a “buy” rating in a research report on Monday, July 19th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $140.43.

About DaVita

DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.

See Also: How To Calculate Debt-to-Equity Ratio

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.